Zacks: Analysts Anticipate Johnson & Johnson (NYSE:JNJ) to Announce $2.55 Earnings Per Share

Equities research analysts expect that Johnson & Johnson (NYSE:JNJGet Rating) will announce earnings of $2.55 per share for the current fiscal quarter, Zacks reports. Five analysts have provided estimates for Johnson & Johnson’s earnings, with estimates ranging from $2.41 to $2.68. Johnson & Johnson posted earnings of $2.48 per share in the same quarter last year, which would indicate a positive year-over-year growth rate of 2.8%. The firm is scheduled to report its next earnings report on Monday, January 1st.

On average, analysts expect that Johnson & Johnson will report full-year earnings of $10.20 per share for the current year, with EPS estimates ranging from $10.15 to $10.27. For the next year, analysts anticipate that the firm will post earnings of $10.75 per share, with EPS estimates ranging from $10.49 to $11.00. Zacks Investment Research’s EPS averages are an average based on a survey of research firms that follow Johnson & Johnson.

Johnson & Johnson (NYSE:JNJGet Rating) last issued its quarterly earnings data on Tuesday, April 19th. The company reported $2.67 earnings per share for the quarter, beating analysts’ consensus estimates of $2.61 by $0.06. Johnson & Johnson had a return on equity of 37.03% and a net margin of 20.90%. The firm had revenue of $23.43 billion during the quarter, compared to analyst estimates of $23.62 billion. During the same quarter last year, the firm earned $2.59 EPS. Johnson & Johnson’s quarterly revenue was up 5.0% on a year-over-year basis.

Several brokerages have recently commented on JNJ. Sanford C. Bernstein lowered Johnson & Johnson from an “outperform” rating to a “market perform” rating and lifted their target price for the stock from $180.00 to $183.00 in a research report on Wednesday, March 16th. Credit Suisse Group lifted their target price on Johnson & Johnson from $200.00 to $205.00 and gave the stock an “outperform” rating in a research report on Wednesday, April 20th. StockNews.com lowered Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a research report on Saturday. Raymond James lifted their target price on Johnson & Johnson from $195.00 to $196.00 and gave the stock an “outperform” rating in a research report on Wednesday, April 20th. Finally, Bank of America started coverage on Johnson & Johnson in a research report on Wednesday, March 2nd. They set a “neutral” rating for the company. Four equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $188.57.

Shares of NYSE JNJ opened at $178.29 on Wednesday. Johnson & Johnson has a fifty-two week low of $155.72 and a fifty-two week high of $186.69. The business has a 50 day moving average price of $176.13 and a two-hundred day moving average price of $169.68. The company has a quick ratio of 1.12, a current ratio of 1.35 and a debt-to-equity ratio of 0.41. The firm has a market cap of $468.77 billion, a PE ratio of 24.03, a price-to-earnings-growth ratio of 2.98 and a beta of 0.66.

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 7th. Shareholders of record on Tuesday, May 24th will be paid a dividend of $1.13 per share. The ex-dividend date is Monday, May 23rd. This represents a $4.52 annualized dividend and a yield of 2.54%. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.06. Johnson & Johnson’s payout ratio is presently 57.14%.

In other Johnson & Johnson news, VP Thibaut Mongon sold 23,681 shares of Johnson & Johnson stock in a transaction on Thursday, March 17th. The stock was sold at an average price of $176.25, for a total transaction of $4,173,776.25. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider William Hait sold 29,699 shares of the business’s stock in a transaction on Thursday, April 21st. The stock was sold at an average price of $183.58, for a total value of $5,452,142.42. Following the completion of the sale, the insider now directly owns 80,236 shares in the company, valued at approximately $14,729,724.88. The disclosure for this sale can be found here. 0.35% of the stock is owned by insiders.

Several institutional investors and hedge funds have recently bought and sold shares of the company. Pinkerton Retirement Specialists LLC raised its stake in shares of Johnson & Johnson by 12.1% in the 1st quarter. Pinkerton Retirement Specialists LLC now owns 16,191 shares of the company’s stock worth $2,870,000 after buying an additional 1,750 shares in the last quarter. Windsor Capital Management LLC grew its holdings in shares of Johnson & Johnson by 1.2% in the 1st quarter. Windsor Capital Management LLC now owns 7,060 shares of the company’s stock worth $1,251,000 after acquiring an additional 82 shares during the last quarter. Trillium Asset Management LLC grew its holdings in shares of Johnson & Johnson by 149.8% in the 1st quarter. Trillium Asset Management LLC now owns 49,029 shares of the company’s stock worth $8,689,000 after acquiring an additional 29,399 shares during the last quarter. Walter Public Investments Inc. acquired a new position in shares of Johnson & Johnson in the 1st quarter worth $15,726,000. Finally, IAG Wealth Partners LLC grew its holdings in shares of Johnson & Johnson by 11.4% in the 1st quarter. IAG Wealth Partners LLC now owns 682 shares of the company’s stock worth $121,000 after acquiring an additional 70 shares during the last quarter. 68.78% of the stock is currently owned by institutional investors.

About Johnson & Johnson (Get Rating)

Johnson & Johnson researches and develops, manufactures, and sells various products in the healthcare field worldwide. It operates in three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Featured Articles

Get a free copy of the Zacks research report on Johnson & Johnson (JNJ)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.